SABS · SAB Biotherapeutics, Inc. · Metrics
$2.83
+0.23 (+8.85%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$236.56M
Shares
90.99M
Volume · Oct 20
814.42K
Avg daily vol (3M)
534.24K
SABS metrics
65 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$2.88
Market cap
$236.56M
Price action
20 metricsPrice change (1W)
-8.1%
Price change (30D)
-23.3%
Price change (3M)
-25.9%
Price change (6M)
-32.6%
Price change (YTD)
-30.5%
Price change (1Y)
+3.6%
Trailing year
Price change (5Y)
—
52-week high
$4.59
52-week low
$2.49
Change from 52-week high
-43.4%
Change from 52-week low
+4.4%
Annualized volatility
58.9%
Annualized volatility (3M)
43.1%
Beta
1.1
RSI (14D)
31.2
Price vs SMA 50
-23.3%
Price vs SMA 200
-30.0%
Avg volume (3M)
528,554
Relative volume
1.1
Average dollar volume
$1.77M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
90.99M
Valuation
12 metricsP / E (TTM)
11.3
Trailing earnings · reciprocal yield 8.8%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
82.8×
reciprocal yield 1.2%
P / book
1.1
reciprocal yield 93.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-5.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.1×
reciprocal yield 89.5%
EV / revenue historical average (5Y)
1.1×
reciprocal yield 89.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-06
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$71.82M
Net income (TTM)
−$12.78M
Trailing 12 months
Diluted EPS (TTM)
$0.23
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+207.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.78M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+758.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-5.9%
Return on assets
-5.4%
Debt / equity
0.0
Current ratio
9.2
EBITDA (TTM)
−$68.85M
Free cash flow (TTM)
—
Quick ratio
9.2
Interest coverage
-309.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$99.43M
Latest balance sheet
Cash & equivalents
$8.27M
Total assets
$238.21M
Total debt
$3.20M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$53.94M
Capital expenditures (TTM)
—
R&D (TTM)
$49.27M
SG&A (TTM)
—
Stock compensation (TTM)
$16.68M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
93
13F filer change QoQ
+10
Institutional ownership
76.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
73.0%
Private-fund adviser ownership
71.2%
Active holders' share change QoQ
-10.1%
Holder tenure
3.7
Price vs estimated holder cost
+14.1%
Ownership (registered funds)
1 metricsIndex-fund ownership
5.6%
Short interest
3 metricsShort interest
4.7%
Latest settlement · 5.0 days to cover
Days to cover
5.0d
Short-squeeze score
65 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—